The application of Fe3O4 nanoparticles in cancer research: a new strategy to inhibit drug resistance.

Although much effort has been extended to the efficient cancer therapies, the drug resistance is still a major obstacle in cancer chemotherapeutic treatments. Almost 90% of the cancer therapy failure is caused by the relative problems. Recently, the application of drug coated polymer nanospheres and nanoparticles to inhibit the related drug resistance has attracted much attention. In this report, we have explored a novel strategy to inhibit the multidrug resistance of the targeted tumor cells by combining the unique properties of tetraheptylammonium capped Fe(3)O(4) magnetic nanoparticles with the drug accumulation of anticancer drug daunorubicin. Our results of confocal fluorescence and atomic force microscopy (AFM) as well as electrochemical studies demonstrate the remarkable synergistic effect of Fe(3)O(4) nanoparticles on drug uptake of daunorubicin in leukemia K562 cells. These observations indicate that the interaction between the magnetic nanoparticles Fe(3)O(4) and biologically active molecules on the membrane of leukemia cell lines may contribute to their beneficial effect on cellular uptake so that the synergistic enhanced effect of magnetic nanoparticles Fe(3)O(4) on drug uptake of drug resistance leukemia K562 cells could be observed upon application of the Fe(3)O(4) nanoparticles.

[1]  Miqin Zhang,et al.  Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[2]  Dan Du,et al.  Electrochemical immunoassay of membrane P-glycoprotein by immobilization of cells on gold nanoparticles modified on a methoxysilyl-terminated butyrylchitosan matrix. , 2005, Biochemistry.

[3]  Dominik Wodarz,et al.  Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Leslie-Pelecky,et al.  Iron oxide nanoparticles for sustained delivery of anticancer agents. , 2005, Molecular pharmaceutics.

[5]  C. Murphy,et al.  Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. , 2005, Small.

[6]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[7]  V. Sharma.  Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity. , 2004, Bioconjugate chemistry.

[8]  D. Peer,et al.  Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models , 2004, Cancer Research.

[9]  M. Schnabelrauch,et al.  Synthesis of oligonucleotide‐functionalized magnetic nanoparticles and study on their in vitro cell uptake , 2004 .

[10]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[11]  Byron Ballou,et al.  Noninvasive imaging of quantum dots in mice. , 2004, Bioconjugate chemistry.

[12]  G. Kruh.  Introduction to resistance to anticancer agents , 2003, Oncogene.

[13]  X. M. Li,et al.  Doping of the nanocrystalline semiconductor zinc oxide with the donor indium , 2003 .

[14]  W. Webb,et al.  Water-Soluble Quantum Dots for Multiphoton Fluorescence Imaging in Vivo , 2003, Science.

[15]  S. Franzen,et al.  Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. , 2003, Journal of the American Chemical Society.

[16]  R. Mumper,et al.  Specific association of thiamine-coated gadolinium nanoparticles with human breast cancer cells expressing thiamine transporters. , 2003, Bioconjugate chemistry.

[17]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[18]  Nathan Kohler,et al.  Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. , 2002, Biomaterials.

[19]  C. Cho,et al.  Receptor-mediated delivery of all trans-retinoic acid to hepatocyte using poly(L-lactic acid) nanoparticles coated with galactose-carrying polystyrene. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[20]  A. Maitra,et al.  Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[21]  C. Alexiou,et al.  Locoregional cancer treatment with magnetic drug targeting. , 2000, Cancer research.

[22]  P Couvreur,et al.  Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. , 2000, Biomaterials.

[23]  R Weissleder,et al.  Measuring transferrin receptor gene expression by NMR imaging. , 1998, Biochimica et biophysica acta.

[24]  M. Lück,et al.  Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. , 1998, Journal of biomedical materials research.

[25]  On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[26]  A J Malkin,et al.  Atomic force microscopy studies of living cells: visualization of motility, division, aggregation, transformation, and apoptosis. , 1997, Journal of structural biology.

[27]  R Weissleder,et al.  Magnetically labeled cells can be detected by MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[28]  I. Bosch,et al.  P-glycoprotein multidrug resistance and cancer. , 1996, Biochimica et biophysica acta.

[29]  Gert Storm,et al.  Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system , 1995 .

[30]  Chien Ho,et al.  Intracellular labeling of T‐cells with superparamagnetic contrast agents , 1993, Magnetic resonance in medicine.

[31]  L. Tiefenauer,et al.  Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. , 1993, Bioconjugate chemistry.

[32]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[33]  M. Gottesman,et al.  Is the multidrug transporter a flippase? , 1992, Trends in biochemical sciences.

[34]  I. Pastan,et al.  Magnetic-affinity cell sorting of human multidrug-resistant cells. , 1991, Journal of the National Cancer Institute.

[35]  A. Rolland,et al.  Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. , 1988, Cancer research.